Comparison of ramosetron's and ondansetron's preventive anti-emetic effects in highly susceptible patients undergoing abdominal hysterectomy.
10.4097/kjae.2011.61.6.488
- Author:
Jae Woo LEE
1
;
Hye Jin PARK
;
Juyoun CHOI
;
So Jin PARK
;
Hyoseok KANG
;
Eu Gene KIM
Author Information
1. Deparment of Anesthesiology and Pain Medicine, Eulji General Hospital, College of Medicine, Eulji University, Seoul, Korea. anesthjin@hanmail.net
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Abdominal hysterectomy;
Ondansetron;
PONV;
Ramosetron
- MeSH:
Analgesia, Patient-Controlled;
Antiemetics;
Benzimidazoles;
Female;
Humans;
Hysterectomy;
Incidence;
Nausea;
Ondansetron;
Passive Cutaneous Anaphylaxis;
Postoperative Nausea and Vomiting;
Postoperative Period;
Prospective Studies;
Serotonin 5-HT3 Receptor Antagonists
- From:Korean Journal of Anesthesiology
2011;61(6):488-492
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: This study compared the preventive effects of ramosetron and ondansetron on postoperative nausea and vomiting (PONV) in highly susceptible patients undergoing abdominal hysterectomy. METHODS: In a prospective, randomized, double-blinded study, a total of 120 highly susceptible women (nonsmokers, those receiving opioid-based IV patient-controlled analgesia [PCA]) undergoing abdominal hysterectomy were included in the study. Patients were divided into 2 groups and each group received either 0.3 mg of ramosetron or 4 mg of ondansetron, IV. All patients received fentanyl-based IV PCA during the 48 h postoperative periods. The incidences of PONV and side effects of 5-HT3 antagonists (headache and dizziness) were assessed at 3 intervals (<2 h, 2-24 h and 24-48 h) postoperatively. RESULTS: Patients in the ramosetron group showed a significantly higher ratio of complete response and lower incidence of nausea during the 24-48 h interval after surgery compared with those the ondansetron group. CONCLUSIONS: Ramosetron (0.3 mg) is more effective in preventing delayed PONV in highly susceptible women undergoing abdominal hysterectomy compared with ondansetron (4 mg).
